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Abstract
Rationale Lysergic acid diethylamide (LSD) is used
recreationally and in clinical research. Acute mystical-type
experiences that are acutely induced by hallucinogens are
thought to contribute to their potential therapeutic effects.
However, no data have been reported on LSD-induced mys-
tical experiences and their relationship to alterations of con-
sciousness. Additionally, LSD dose- and concentration-
response functions with regard to alterations of consciousness
are lacking.
Methods We conducted two placebo-controlled, double-
blind, cross-over studies using oral administration of 100
and 200 μg LSD in 24 and 16 subjects, respectively. Acute
effects of LSD were assessed using the 5 Dimensions of
Altered States of Consciousness (5D-ASC) scale after both
doses and theMystical Experience Questionnaire (MEQ) after
200 μg.
Results On the MEQ, 200 μg LSD induced mystical experi-
ences that were comparable to those in patients who
underwent LSD-assisted psychotherapy but were fewer than
those reported for psilocybin in healthy subjects or patients.
On the 5D-ASC scale, LSD produced higher ratings of blissful
state, insightfulness, and changed meaning of percepts after
200μg comparedwith 100 μg. Plasma levels of LSDwere not
positively correlated with its effects, with the exception of ego
dissolution at 100 μg.
Conclusions Mystical-type experiences were infrequent after
LSD, possibly because of the set and setting used in the pres-
ent study. LSD may produce greater or different alterations of
consciousness at 200 μg (i.e., a dose that is currently used in
psychotherapy in Switzerland) compared with 100 μg (i.e., a
dose used in imaging studies). Ego dissolution may reflect
plasma levels of LSD, whereas more robustly induced effects
of LSD may not result in such associations.
Keywords LSD . Altered states of consciousness . Mystical
experiences
Introduction
Lysergic acid diethylamide (LSD) is the prototypical halluci-
nogen (Nichols 2016; Passie et al. 2008). LSD became fa-
mous, with a high cultural influence, in the 1960s. LSD con-
tinues to be used for recreational and personal purposes
(Krebs and Johansen 2013). Additionally, there is much inter-
est in its therapeutic potential (Baumeister et al. 2014;
Davenport 2016; Gasser et al. 2014; Gasser et al. 2015;
Krebs and Johansen 2012; Kupferschmidt 2014). Only one
modern study has tested the therapeutic effects of LSD in
patients (Gasser et al. 2014), whereas several clinical trials
have recently evaluated the therapeutic potential of psilocybin
(Bogenschutz et al. 2015; Carhart-Harris et al. 2016a; Garcia-
Romeu et al. 2015; Griffiths 2016; Grob et al. 2011; Guss
2016), a similar serotonergic hallucinogen (Rickli et al.
2016). A series of studies showed that psilocybin acutely
The studies were registered at ClinicalTrials.gov (NCT02308969,
NCT01878942).
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induced mystical experiences in healthy subjects and patients
(Garcia-Romeu et al. 2015; Griffiths et al. 2008; Griffiths et al.
2011; Griffiths et al. 2006; MacLean et al. 2011).
Additionally, greater acute effects of psilocybin on the
Mystical Experience Questionnaire (MEQ; Barrett et al.
2015; Griffiths et al. 2006; MacLean et al. 2012) were asso-
ciated with positive long-term effects onmood and personality
in healthy subjects (Griffiths et al. 2008; Griffiths et al. 2011;
Griffiths et al. 2006; MacLean et al. 2011) and better thera-
peutic outcomes in patients with anxiety, depression, and sub-
stance use disorder (Garcia-Romeu et al. 2015; Griffiths 2016;
Griffiths et al. 2008; Griffiths et al. 2011; Griffiths et al. 2006;
MacLean et al. 2011). Early studies reported on mystical
experiences after experimental administration of LSD, but
methodological details are missing (Turek et al. 1974).
Whether and the extent to which LSD produces mystical-
type effects in the MEQ are currently unknown. Therefore,
we characterized the effects of 200 μg LSD on the MEQ
and evaluated the way in which mystical experiences are
related to LSD-induced increases in 5 Dimensions of
Altered States of Consciousness (5D-ASC) scale scores
and plasma levels of LSD.
Clinical experimental research with LSD has recently seen a
resurgence (Carhart-Harris et al. 2016b; Carhart-Harris et al.
2015; Carhart-Harris et al. 2016c; Dolder et al. 2015b; Dolder
et al. 2016; Kaelen et al. 2015; Kaelen et al. 2016; Lebedev et al.
2016; Roseman et al. 2016; Schmid et al. 2015; Speth et al.
2016; Strajhar et al. 2016; Tagliazucchi et al. 2016; Terhune
et al. 2016). An increasing amount of data has been generated
on the effects of LSD (75 μg) on various neuronal correlates of
brain activation (Carhart-Harris et al. 2016c; Kaelen et al. 2016;
Lebedev et al. 2016; Roseman et al. 2016). Researchers have
correlated subjective drug effects with brain functional magnetic
resonance imaging (fMRI) data (Carhart-Harris et al. 2016c;
Kaelen et al. 2016; Lebedev et al. 2016; Roseman et al. 2016).
This approach likely produces significant findings for subjective
effects that show large between-subject variance but not for sub-
jective effects of the substance that are consistently present in all
subjects. Lower doses of LSD may also result in more variable
responses across subjects compared with higher doses.
Furthermore, higher doses of LSD (e.g., 200 μg) that are cur-
rently used therapeutically (Gasser et al. 2014) may produce
more pronounced but also qualitatively different subjective ef-
fects (Dolder et al. 2016). Importantly, plasma concentrations of
LSD have not been determined in any of the published LSD
fMRI studies to date; therefore, unclear is the way in which
LSD exposure in the body is linked to subjective effects in these
studies. Therefore, a second goal of the present study was to
describe the subjective peak effects of two doses of LSD (100
and 200 μg) using the 5D-ASC scale (Studerus et al. 2010). The
5D-ASC scale has been used in all of the recent experimental
studies with LSD (Carhart-Harris et al. 2016b; Carhart-Harris
et al. 2016c; Schmid et al. 2015; Tagliazucchi et al. 2016) and
with many other psychedelics, providing an opportunity to com-
pare findings between studies and across substances and research
groups. Thus, the present study assessed LSD dose- and plasma
concentration-response functions using the 5D-ASC scale in 40
subjects (Dolder et al. 2015b; Dolder et al. 2016; Schmid et al.
2015), thus allowing comparisons with other studies that used
the 5D-ASC scale but did not determine plasma LSD concentra-
tions (Carhart-Harris et al. 2016b; Carhart-Harris et al. 2016c;
Kaelen et al. 2016; Lebedev et al. 2016; Roseman et al. 2016;
Speth et al. 2016; Tagliazucchi et al. 2016; Terhune et al. 2016).
A third goal of the present studywas to assess associations across
subjects between the peak and total plasma exposure to LSD and
its effects on 5D-ASC scale scores (Studerus et al. 2010). The
effects of 100 μg LSD on 5D-ASC scale scores are reported for
the first time in the present study, whereas the effects of 200 μg
have been previously published (Schmid et al. 2015). However,
the latter study did not evaluate dose- or concentration-response
functions. Other data that were generated in the present study
have been previously reported including acute and subacute ad-
verse effects (Dolder et al. 2015b; Dolder et al. 2016; Schmid
et al. 2015; Strajhar et al. 2016).
Material and methods
Study design
We performed two similar studies using double-blind, place-
bo-controlled, cross-over designs with two experimental test
sessions (LSD and placebo) in a balanced order. Study 1 used
a dose of 100 μg LSD and placebo in 24 subjects. Study 2
used 200 μg LSD and placebo in 16 subjects. The washout
periods between sessions were at least 7 days. The studies
were conducted in accordance with the Declaration of
Helsinki and approved by the local ethics committee. The
administration of LSD to healthy subjects was authorized by
the Swiss Federal Office for Public Health, Bern, Switzerland.
All of the subjects provided written consent before participat-
ing in either of the studies, and they were paid for their par-
ticipation. The studies were registered at ClinicalTrials.gov
(NCT02308969, NCT01878942).
Participants
Forty healthy participants were recruited from the University
of Basel campus via online advertisement. Twenty-four sub-
jects (12 men, 12 women; 33 ± 11 years old [mean ± SD];
range, 25–60 years) participated in study 1, and 16 subjects (8
men, 8 women; 29 ± 6 years old; range, 25–51 years) partic-
ipated in study 2. The inclusion and exclusion criteria were
identical for both studies. Subjects younger than 25 years of
age were excluded from participating in the study. Additional
exclusion criteria were age >65 years, pregnancy (urine
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pregnancy test at screening and before each test session), per-
sonal or family (first-degree relative) history of major psychi-
atric disorders (assessed by the semi-structured clinical inter-
view for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, Axis I disorders by the study physician
and an additional interview by a trained psychiatrist), use of
medications that may interfere with the study medication,
chronic or acute physical illness (abnormal physical exam,
electrocardiogram, or hematological and chemical blood anal-
yses), tobacco smoking (>10 cigarettes/day), lifetime preva-
lence of illicit drug use >10 times (except for tetrahydrocan-
nabinol), illicit drug use within the last 2 months, and illicit
drug use during the study (determined by urine drug tests).
The subjects were asked to abstain from excessive alcohol
consumption between test sessions and particularly limit their
use to one standard drink on the day before the test sessions.
Additionally, the participants were not allowed to drink
xanthine-containing liquids after midnight before the study
day. Eleven subjects had used a hallucinogen, including
LSD (six participants), one to three times, and most of the
subjects (29) were hallucinogen-naive. We performed urine
drug tests at screening and before each test session, and no
substances were detected during the study.
Study procedures
Each study included a screening visit, a psychiatric interview,
two 25-h experimental sessions, and an end-of-study visit. The
experimental sessions were conducted in a quiet standard hos-
pital patient room. The participants were resting in hospital beds
except when going to the restroom. Only one research subject
and one or two investigators were present during the experi-
mental sessions. The participants could interact with the inves-
tigator, rest quietly, and/or listen to music via headphones, but
no other entertainment was provided. LSD or placebo was ad-
ministered at 9:00 AM. The subjects were never alone during
the first 12 h after drug administration, and the investigator was
in a room next to the subject for up to 24 h while the subjects
were asleep (mostly from 1:00 AM to 8:00 AM).
Study drug
LSD (d-LSD hydrate, HPLC purity >99 %, Lipomed AG,
Arlesheim, Switzerland) was administered in single oral doses
of 100 or 200 μg as gelatin capsules. Note that these LSD
hydrate doses correspond to LSD tartrate doses of 123 and
246 μg, respectively. In the 1960–1970s, small doses of
LSD tartrate of 25–150 μg were typically used in “psycholytic
therapy” and higher doses of >200 μg in “psychedelic” ther-
apy (Pahnke et al. 1970). The dose used in a recent LSD-
assisted psychotherapy study was 200 μg LSD hydrate
(Gasser et al. 2014). Both doses used in the present study were
within the range of doses that are taken for recreational
purposes (Passie et al. 2008). Corresponding placebo capsules
were used.
Measures
Mystical-type experiences In study 2, mystical experiences
were assessed using a German version (Supplementary
Appendix 1) of the 43-item MEQ (Griffiths et al. 2006;
MacLean et al. 2012; Pahnke 1969) embedded in the 100-
item States of Consciousness Questionnaire (SOCQ; (Griffiths
et al. 2006). The original English questionnaire was indepen-
dently forward-translated into German by two translators with
German as their mother tongue. Discrepancies between the two
forward-translated versions and a previous German version
were then discussed and selected items backtranslated. The
version was then pretested for comprehension by persons with
previous LSD or MDMA use.
The MEQ has been used in numerous experimental and
therapeutic trials with psilocybin (Garcia-Romeu et al. 2015;
Griffiths et al. 2008; Griffiths et al. 2011; Griffiths et al. 2006;
MacLean et al. 2011). The MEQ items provide scale scores for
each of seven domains of mystical experiences: internal unity,
external unity, sacredness, noetic quality (as real as or more real
than everyday reality), deeply felt positive mood, transcendence
of time and space, and ineffability/paradoxicality (difficulty de-
scribing the experience in words). The total of all scale scores
was used as an overall measure of the mystical-type experience.
We also derived the four scale scores of the newly validated
revised 30-item MEQ: mystical, positive mood, transcendence
of time and space, and ineffability (Barrett et al. 2015). A com-
plete mystical experience was defined as scores ≥60 % on all
MEQ30 factors (Barrett et al. 2015). TheMEQwas administered
24 h after drug administration, and the participants were asked to
retrospectively rate drug effects during peak drug effects. For
comparison, we included MEQ ratings that were obtained 6 h
after administration of 3,4-methylenedioxymethamphetamine
(MDMA) and methylphenidate in another study using a similar
research setting (Schmid et al. 2014). Additionally, we included
MEQ ratings from patients who were treated with 200 μg LSD
for anxiety related to life-threatening illness in another study
(Diesch 2015; Gasser et al. 2014; Gasser et al. 2015). All of these
additional MEQ findings have not been previously published in
scientific journals and were obtained in studies that were previ-
ously described in detail (Diesch 2015; Gasser et al. 2014;Gasser
et al. 2015; Schmid et al. 2014).
Alterations of consciousness The 5D-ASC scale was used in
both studies to assess the overall peak alterations of conscious-
ness. The 5D-ASC scale measures altered states of conscious-
ness and contains 94 items (visual analog scales). The instru-
ment consists of five subscales/dimensions (Dittrich 1998)
and 11 lower-order scales (Studerus et al. 2010). The 5D-
ASC dimension “Oceanic Boundlessness” (27 items)
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measures derealization and depersonalization associated with
positive emotional states, ranging from heightened mood to
euphoric exaltation. The corresponding lower-order scales in-
clude “experience of unity,” “spiritual experience,” “blissful
state,” and “insightfulness.” The dimension “Anxious Ego
Dissolution” (21 items) summarizes ego disintegration and
loss of self-control phenomena associated with anxiety. The
corresponding lower-order scales include “disembodiment,”
“impaired control of cognition,” and “anxiety.” The dimen-
sion “Visionary Restructuralization” (18 items) consists of the
lower-order scales “complex imagery,” “elementary imagery,”
“audio-visual synesthesia,” and “changed meaning of per-
cepts.” Two additional dimensions describe “Auditory
Alterations” (15 items) and “Reduction of Vigilance” (12
items). The scale is well-validated and widely used to charac-
terize the subjective effects of various psychedelic drugs
(Carhart-Harris et al. 2016b; Hasler et al. 2004; Hysek et al.
2011; Schmid et al. 2015; Vollenweider et al. 2007;
Vollenweider and Kometer 2010). In addition to the subscale
analyses, we also analyzed the effects on ego dissolution item
71 (the boundaries between myself and my surroundings
seemed to blur) because the concept of ego dissolution was
often used in recent imaging studies (Tagliazucchi et al. 2016).
The 5D-ASC scale was administered 24 h after drug admin-
istration, and the participants were asked to retrospectively
rate the drug effects. 5D-ASC ratings were also performed at
3 and 10 h in study 1.
Analysis of plasma LSD concentrations
Blood was collected into lithium heparin tubes before and 0.5,
1, 1.5, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD admin-
istration. The 0.5, 1.5, and 2.5 h samples were not collected in
study 1. Blood samples were immediately centrifuged, and the
plasma was rapidly stored at −20 °C and later analyzed using
liquid-chromatography-tandem mass-spectrometry as previ-
ously reported (Dolder et al. 2015a; Steuer et al. 2016).
Maximal plasma concentrations (Cmax) and total exposure (ar-
ea under the plasma concentration-time curve [AUC]) were
estimated using compartmental modeling in Phoenix
WinNonlin 6.4 (Certara, Princeton, NJ, USA). A one-
compartment model was used with first-order input, first-
order elimination, and no lag time.
Statistical analyses
The data analysis was performed using Statistica 12 software
(StatSoft, Tulsa, OK, USA). Differences between LSD and
placebo or between the 100 and 200 μg doses of LSD were
compared using dependent or independent t tests, respectively.
Associations between outcome measures were assessed using
Pearson correlations. Significance was assumed at p < 0.05.
Results
Mystical-type experiences
LSD (200 μg) significantly increased all MEQ scores com-
pared with placebo (Fig. 1a, Table 1). The effects of MDMA
and methylphenidate on MEQ scores are included for com-
parison (Fig. 1a). The effects of LSD (200 μg) and placebo on
MEQ scores in 11 patients during LSD-assisted psychothera-
py (Gasser et al. 2014) are also shown in Fig. 1b. LSD-
induced mystical experiences were comparable in healthy
subjects in the laboratory setting in the present study and in
patients in the therapeutic setting (Fig. 1b). Only two subjects
in each of the studies had a complete mystical experience. The
MEQ30 total scores were <5 % in both settings after placebo
administration (Fig. 1b).
Alterations of consciousness
LSD induced pronounced peak alterations of waking con-
sciousness, with significant increases in all dimensions and
subscales of the 5D-ASC scale (Fig. 2). The 200 μg dose of
LSD produced significantly greater scores on the overall ASC
scale, the dimension of visionary restructuralization, and the
blissful state, insightfulness, and changed meaning of percepts
subscales comparedwith the 100μg dose (Fig. 2, Table 1). The
mean ± SEM ego dissolution (item 71) scores were 49 ± 6 and
53 ± 10 after the 100 and 200 μg doses, respectively (Table 1).
There were only minimal differences between the 5D-ASC
ratings at 3, 10, and 24 h (supplementary Fig. S1 online).
Plasma LSD concentrations
Plasma concentrations varied between subjects, especially at
the lower 100 μg dose. The median (range) Cmax values were
1.4 ng/ml (0.32–3.7) and 3.2 ng/ml (1.9–7.1) for the 100 and
200 μg doses, respectively. The corresponding AUC values
were 8.5 ng × h/ml (1–19) and 20.7 ng × h/ml (11–39).
Associations between alterations of consciousness
and mystical-type experiences
Table 2 shows the cross-tabulation of all correlations between
the 5D-ASC scale and MEQ30 subscale ratings. LSD-induced
alterations of consciousness (ASC total score) were significant-
ly correlated with ratings of mystical experience (MEQ30 total
score) on the MEQ (Rp = 0.87, p < 0.001, n = 16; Fig. 3).
Scores on the MEQ positive mood scale were strongly associ-
ated with scores on the ASC experience of unity and blissful
state scales (Rp = 0.85 and 0.80, respectively; both p < 0.001,
n = 16; Table 2).
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Correlations between plasma LSD concentrations
and LSD-induced alterations of consciousness
and mystical-type experiences
The Cmax and AUC values for LSD were not positively
correlated with ratings of peak subjective effects on the
5D-ASC scale or MEQ across subjects or within dose
groups (Table 3). For example, LSD induced consistently
high ratings of audio-visual synesthesia in almost all of
the subjects at the high dose (200 μg), resulting in little
within-subject variance and no association with plasma
exposure to LSD (Table 3, Fig. 4a). One exception was
ego dissolution (item 71) at the lower dose of LSD
(100 μg; Table 3, Fig. 4b). The ratings showed high
Fig. 1 Effects of LSD on theMystical Experience Questionnaire (MEQ).
a In the present study in healthy subjects, LSD (200 μg) significantly
increased scores on all scales of the MEQ43 and MEQ30 compared with
placebo (Table 1). The data are expressed as the mean ± SEM in 16
subjects. For comparison, 3,4-methylenedioxymethamphetamine
(MDMA; 75 mg) and methylphenidate (40 mg) produced small
increases in MEQ ratings in 30 different participants in another study in
the same research setting (Schmid et al. 2014). b Effects of LSD on the
MEQ in patients with anxiety in the context of life-threatening illness.
The data were analyzed identically to the data that were obtained in the
present study. The study and patient characteristics have been previously
published in detail (Diesch 2015; Gasser et al. 2014; Gasser et al. 2015;
Schmid et al. 2014). Similar to the present study, the MEQ was
administered on the day after LSD (200 μg) or active placebo (25 μg
LSD) administration and was embedded into the larger 100-item States of
Consciousness Questionnaire (SOCQ; Griffiths et al. 2006). The patient
data are expressed as the mean ± SEM in 11 subjects for LSD (200 μg,
same formulation as in the present study) and four subjects for placebo.
On the 43- and 30-item versions of the MEQ, LSD (200 μg) increased
MEQ rating scores in the patients in the therapeutic setting (b) to a similar
extent as in the healthy subjects in the present study (a). Notably, the
placebo response (a very low dose of LSD of 25 μg was used as the
active placebo) in the patients was small (b), which was also similar to
the response in healthy subjects in the present study (a)
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interindividual variance, and there was a significant pos-
itive correlation with the LSD AUC value in the 100 μg
dose group (Rp = 0.51, p < 0.05, n = 16; Table 3,
Fig. 4b). At the 200 μg dose, there were significant neg-
ative correlations between Cmax values for LSD and sub-
jective effects on the 5D-ASC scale including visionary
restructuralization, elementary imagery, and changed
meaning of percepts.
Discussion
The present study characterized LSD-induced mystical
experiences using the MEQ after a dose of 200 μg
and alterations of consciousness on the 5D-ASC scale
after a dose of 100 μg. The study also evaluated asso-
ciations between plasma LSD concentrations and these
subjective effects.
Table 1 Statistics for the effects
of LSD in the 5D-ASC and MEQ LSD 100 μg
T test vs. placebo
LSD 200 μg
T test vs. placebo
LSD 100 vs. 200 μg
T test
T= P= T= P= T= P=
5 Dimensions Altered States of Consciousness (ASC) scale
Total ASC score 9.72 <0.001 10.02 <0.001 2.23 <0.05
Oceanic boundlessness 8.44 <0.001 9.61 <0.001 1.89 NS
Anxious ego dissolution 6.43 <0.001 4.01 <0.001 1.50 NS
Visionary restructuralization 9.79 <0.001 15.32 <0.001 2.34 <0.05
Auditory alterations 3.72 <0.01 5.87 <0.001 0.42 NS
Reductions of vigilance 7.44 <0.001 5.93 <0.001 0.79 NS
Experience of unity 6.85 <0.001 7.77 <0.001 0.68 NS
Spiritual experience 4.31 <0.001 3.91 <0.001 1.10 NS
Blissful state 6.56 <0.001 8.27 <0.001 3.00 <0.01
Insightfulness 4.11 <0.001 5.81 <0.001 2.28 <0.05
Disembodiment 6.93 <0.001 5.87 <0.001 0.13 NS
Impaired control and cognition 7.01 <0.001 5.04 <0.001 0.86 NS
Anxiety 3.02 <0.001 2.04 NS 1.37 NS
Complex imagery 7.10 <0.001 7.48 <0.001 0.31 NS
Elementary imagery 9.96 <0.001 11.12 <0.001 0.57 NS
Audio-visual synsthesia 9.19 <0.001 12.52 <0.001 1.96 NS
Changed meaning of percepts 6.25 <0.001 9.66 <0.001 3.39 <0.01
Ego dissolution (item 71) 7.63 <0.001 5.32 <0.001 0.36 NS
Mystical Effects Questionnaire (MEC43)
Internal unity NA NA 6.22 <0.001 NA NA
External unity NA NA 6.08 <0.001 NA NA
Sacredness NA NA 6.80 <0.001 NA NA
Noetic quality NA NA 5.71 <0.001 NA NA
Deeply felt positive mood NA NA 11.43 <0.001 NA NA
Transcendence of time/space NA NA 10.63 <0.001 NA NA
Ineffability NA NA 16.22 <0.001 NA NA
Mystical Effects Questionnaire (MEQ30)
Mystical NA NA 5.99 <0.001 NA NA
Positive mood NA NA 13.13 <0.001 NA NA
Transcendence of time/space NA NA 11.12 <0.001 NA NA
Ineffability NA NA 25.14 <0.001 NA NA
MEC30 total score NA NA 14.91 <0.001 NA NA
Sixteen subjects participated in the high-dose study (200μg) and 24 subjects in the moderate-dose study (100μg).
Dependent T tests were performed to assess differences from placebo, and independent T tests were performed to
assess differences between doses of LSD
NA not assessed
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LSD produced mean MEQ30 total score ratings of 61 %
(range 40–98 %) and a complete mystical experience in only
two participants (12.5 %). The MEQ has typically been used
with psilocybin, and data on MEQ30 scores are available for
various doses of psilocybin, placebo, and methylphenidate
(active placebo; Barrett et al. 2015). Psilocybin (at the highest
studied dose of 30 mg/70 kg) produced a high mean MEQ30
total score rating of 77 % and complete mystical experiences
in as many as 67 % of healthy subjects (Barrett et al. 2015).
However, in this psilocybin study setting, inactive and active
placebo (methylphenidate) also produced high mean MEQ30
ratings of 23 and 33 %, respectively (Barrett et al. 2015). In
contrast, in the present study, placebo increased MEQ30
scores only to 1 %. Similarly, MDMA and methylphenidate
produced only small increases in MEQ scores in a similar
laboratory setting (Schmid et al. 2014). Another study evalu-
ated psilocybin-assisted psychotherapy in tobacco smokers
and also found complete mystical experiences in only 10 of
26 sessions (38 %) that were conducted in 14 patients with
high-dose psilocybin (30 mg/70 kg; Garcia-Romeu et al.
2015; Johnson et al. 2014). Accounting for the higher placebo
ratings in some of the psilocybin studies compared with our
study, LSD increased MEQ30 score differences from placebo
overall more than psilocybin and produced greater ineffability
and positive mood but lower effects on the mystical subscale
than psilocybin (Barrett et al. 2015).
Additionally, the MEQ has been used in patients with anx-
iety associated with life-threatening illness who were treated
with 200 μg LSD (Gasser et al. 2014; Gasser et al. 2015). In
this therapeutic setting, LSD produced similar mystical expe-
riences as in the present study and complete mystical experi-
ences in only two of 11 patients. MEQ scores were only within
the range of 3–9 % after active placebo administration (25 μg
LSD) on the MEQ subscales. Altogether, these findings indi-
cate that mainly the placebo response and/or the expectancy of
a mystical experience were greater in the study setting in some
psilocybin studies compared with the LSD studies.
Additionally, the participants in the psilocybin studies may
have been more spiritually inclined (Griffiths et al. 2006) than
our study participants leading to more mystical experiences
(Studerus et al. 2012). Furthermore, others may have provided
more extensive preparation of the subjects and interpersonal
support, contributing to mystical experiences.
The present findings do not support the view that LSD
produces lower overall effects than psilocybin at the doses
tested. In contrast, the high dose of LSD (200 μg) produced
greater placebo-adjusted positive mood ratings than psilocy-
bin on the MEQ30 (Barrett et al. 2015) and very pronounced
increases in 5D-ASC blissful state ratings and produced far
greater effects than the highest doses of psilocybin or dimeth-
yltryptamine (DMT) that were tested so far on this scale
(Gouzoulis-Mayfrank et al. 2005; Hasler et al. 2004).
Additionally, LSD-induced MEQ scores were highly correlat-
ed with 5D-ASC scores in the present study.
One could argue that mystical and spiritual experiences are
not the most prominent feature of the LSD response. Mean
ratings on the spiritual experience scale of the 5D-ASC were
22 and 33 % at the 100 and 200 μg doses, respectively, in the
Fig. 2 Effects of LSD on the 5 Dimensions of Altered States of
Consciousness (5D-ASC) scale. LSD mainly increased ratings of oceanic
boundlessness (OB) and visionary restructuralization (VR), with
significantly higher ratings for the ASC total score and VR dimension at
200 μg compared with 100 μg. LSD-induced increases in anxious ego
dissolution (AED) and auditory alterations (AA) were relatively small.
LSD also produced vigilance reduction (VIR). LSD-induced changes on
the 5D-ASC scale were significant compared with placebo for both doses
and all of the scales, with the exception of the effects of the 200 μg dose on
anxiety (Table 1). At 200 μg, LSD produced significant and relevantly
higher ratings of blissful state, insightfulness, and changed meaning of
percepts compared with 100 μg (one asterisk p < 0.05, two asterisks
p < 0.01, t tests). The data are expressed as the mean ± SEM in 24
subjects and 16 subjects for the 100 and 200 μg doses of LSD, respectively
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present study and approximately 23 % after 75 μg LSD in
another study (Carhart-Harris et al. 2016c). Mean ratings of
“the experience had a spiritual or mystical quality” were also
only approximately 28 % in an imaging study that evaluated
the effects of LSD (Tagliazucchi et al. 2016). However, a
direct within-subjects comparison of LSD and psilocybin
in the same research setting is needed to determine possible
differences in mystical-type responses between these sub-
stances. Whether mystical-type experiences (Barrett et al.
2015; Garcia-Romeu et al. 2015; MacLean et al. 2011) are
critical for the therapeutic potential of substance-assisted
psychotherapy requires further study. At least in the case
of LSD, the mystical experiences (MEQ scores) were high-
ly associated with other alterations of consciousness on the
5D-ASC scale, and LSD produced additional effects on
emotion processing that could facilitate psychotherapeutic
interventions (Dolder et al. 2016).
Recent experimental studies associated the subjective ef-
fects of LSD (75 μg, intravenous) on the 5D-ASC scale with
fMRI data but in the absence of data on plasma LSD levels
Fig. 3 LSD-induced alterations of consciousness are significantly
associated with the LSD-induced mystical experience. The data are
expressed as a percentage of ASC total scores on the 5D-ASC scale and
a percentage of total scores on theMEQ30 for each of 16 participants after
administration of 200 μg LSD. The lines indicate the regression and 95%
confidence intervals (Rp = 0.87, p < 0.001)
Table 2 Associations between
LSD-induced alterations in
consciousness (5D-ASC) and
mystical experiences (MEQ30)
Mystical Effects Questionnaire (MEQ30)
MEQ30 total
score
Mystical Positive
mood
Transcendence of
time/space
Ineffability
5D-ASC scale
Total ASC score 0.87 0.73 0.65 0.82 0.57
Oceanic boundlessness 0.93 0.88 0.83 0.74 0.45
Anxious ego
dissolution
0.60 0.39 0.35 0.68 0.55
Visionary
restructuralization
0.65 0.54 0.38 0.68 0.45
Auditory alterations 0.30 0.14 0.02 0.49 0.38
Reductions of
vigilance
0.61 0.41 0.47 0.64 0.47
Experience of unity 0.82 0.86 0.85 0.56 0.25
Spiritual experience 0.79 0.76 0.76 0.60 0.33
Blissful State 0.80 0.77 0.80 0.72 0.16
Insightfulness 0.77 0.79 0.68 0.52 0.42
Disembodiment 0.71 0.53 0.62 0.71 0.41
Impaired control and
cognition
0.63 0.37 0.45 0.79 0.46
Anxiety 0.45 0.32 0.19 0.47 0.51
Complex imagery 0.48 0.31 0.32 0.69 0.19
Elementary imagery 0.36 0.37 0.08 0.29 0.42
Audio-visual
synesthesia
0.23 0.07 0.22 0.45 −0.01
Changed meaning of
percepts
0.80 0.67 0.59 0.70 0.63
Ego dissolution (item
71)
0.74 0.73 0.74 0.65 0.12
Values are Pearson correlation coefficients in 16 subjects describing correlations between %5D-ASC and
%MEQ30 scores. Bold values for P < 0.05, italic values for P < 0.001
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(Carhart-Harris et al. 2016c; Kaelen et al. 2016; Lebedev et al.
2016; Roseman et al. 2016). Assuming high oral bioavailabil-
ity of LSD of 70–100 % (Dolder et al. 2015b), similar plasma
exposure (AUC) can be assumed after oral administration of
100 μg LSD (present study I) or intravenous administration of
75 μg LSD (all studies by Carhart-Harris and colleagues).
Supporting this assumption, the intravenous 75 μg dose of
LSD produced very similar mean ratings on the 5D-ASC scale
(Carhart-Harris et al. 2016b) to the present study that used an
oral dose of 100 μg. In contrast, the 200 μg dose produced
significantly greater ASC total scores and particularly greater
5D-ASC subscale scores of blissful state, insightfulness, and
changed meaning of percepts. As previously reported, the
200 μg dose of LSD also produced greater feelings of close-
ness to others, happiness, openness, and trust than the 100 μg
dose (Dolder et al. 2016). Altogether, the data indicate that the
200 μg dose produces overall greater effects and particularly
more positive and MDMA-like effects than lower doses
(Dolder et al. 2016). This is relevant because the higher dose
is currently being used in LSD-assisted psychotherapy
(Gasser et al. 2014; Gasser et al. 2015), and the lower dose
is being tested in experimental fMRI studies (Carhart-Harris
et al. 2016c). The 200 μg dose of LSD also produced greater
ASC scores than high doses of the serotonergic hallucinogens
DMTand psilocybin (Gouzoulis-Mayfrank et al. 2005; Hasler
et al. 2004; Vollenweider and Kometer 2010), ketamine
(Gouzoulis-Mayfrank et al. 2005; Studerus et al. 2010), and
MDMA (Hysek et al. 2011), although direct comparisons
within the same studies and subjects are missing.
The present analyses showed no positive correlations be-
tween LSD levels and effects across subjects, possibly be-
cause of the relatively high levels of LSD and generally
Fig. 4 Correlations between plasma LSD concentrations and subjective
peak effects. a At 200 μg, LSD induced high ratings of audio-visual
synesthesia in all but two of the 16 participants. There was little
variance in the response and no correlation between total plasma
exposure to LSD (area under the concentration-time curve [AUC]) and
audio-visual synesthesia (Rp = 0.0, p > 0.05, n = 16). b In contrast, ego
dissolution was present to highly variable degrees across subjects after
administration of 100 μg LSD. Total exposure to LSD (AUC) positively
correlated with LSD-induced ego dissolution (Rp = 0.51, p < 0.05,
n = 24). The lines indicate the regression and 95 % confidence intervals
Table 3 Associations between predicted maximal LSD plasma
concentrations (Cmax) and LSD exposure (AUC) and alterations in
consciousness (SD-ASC) and mystical experiences (MEQ30)
N = 24 N = 16
100 μg 200 μg
Cmax AUC Cmax AUC
5D-ASC scale
ASC total score 0.19 0.21 −0.35 0.15
Oceanic boundlessness 0.24 0.26 −0.35 0.10
Anxious ego dissolution 0.04 0.07 −0.10 0.32
Visionary restructuralization 0.12 0.15 −0.59 −0.16
Auditory alterations 0.02 0.12 −0.18 0.08
Reductions of vigilance −0.01 0.13 −0.10 0.38
Experience of unity 0.34 0.33 −0.03 0.33
Spiritual experience −0.02 0.06 −0.32 −0.03
Blissful state 0.25 0.14 −0.23 0.03
Insightfulness 0.24 0.20 −0.37 0.12
Disembodiment −0.04 0.08 −0.23 0.08
Impaired control and cognition −0.01 0.01 −0.20 0.18
Anxiety 0.22 0.30 0.01 0.38
Complex imagery 0.06 0.14 −0.28 −0.04
Elementary imagery −0.13 −0.03 −0.53 −0.15
Audio-visual synesthesia 0.23 0.26 −0.01 0.00
Changed meaning of percepts −0.03 −0.06 −0.62 −0.10
Ego dissolution (item 71) 0.40 0.51 −0.27 −0.14
MEQ30
MEC30 total score NA −0.30 0.17
Mystical NA −0.25 0.13
Positive mood NA −0.08 0.21
Transcendence of time/space NA −0.23 0.10
Ineffability NA −0.49 0.13
Values are Pearson correlation coefficients describing correlations, the
peak concentrations of LSD predicted by the one-compartment model,
and LSD-induced %5D-ASC and %MEQ30 scores. Bold values for
P < 0.05Cmax maximal LSD plasma concentration predicted by the one-
compartment pharmacokinetic model, AUC area under the LSD
concentration-time curve predicted by the model
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consistently high subjective response ratings in most subjects.
Thus, if relatively high and similar doses of LSD are used that
result in plasma levels clearly above the EC50 of a particular
response measure, then it is unlikely that the response varies
relevantly across subjects because responses are close to max-
imal. This would typically also be the case with measures with
a maximal effect limit such as VAS ratings and some physio-
logical effects like pupil size (Hysek and Liechti 2012).
In fact, responses to MDMA or LSD or other drugs in a
standardized experimental setting may vary only if the re-
sponse is not induced consistently in all subjects (e.g., at the
beginning of the response) and are mostly attributable to indi-
vidual differences in drug absorption/distribution (Hysek and
Liechti 2012) or when a response is evaluated that is not ro-
bustly induced or when a lower dose is used. Specifically,
correlations of plasma levels with the subjective and cardio-
vascular effects of MDMA across subjects are only weak dur-
ing the peak response but stronger at onset (Hysek and Liechti
2012). This is an important consideration. For example, LSD-
induced subjective ego dissolution was recently shown to be
associated with specific brain activation patterns in a study
that administered a relatively low dose of LSD of 75 μg intra-
venously (Tagliazucchi et al. 2016). Interestingly, LSD-
induced ego dissolution correlated with plasma LSD levels
after administration of an equivalent oral dose of 100 μg in
the present study, and this was the only pharmacodynamic
effect of LSD for which a positive association with plasma
levels could be demonstrated across subjects. This finding
needs to be kept in mind when interpreting associations be-
tween ego dissolution and fMRI parameters because the fMRI
findings may also reflect other processes that are related to the
plasma levels of LSD. Furthermore, the likelihood of detect-
ing correlations within a dose group increases for effects that
are not robustly induced in all subjects and thus for effects that
are not typically present in all subjects after LSD administra-
tion. Finally, unclear is the extent to which a full LSD re-
sponse was induced in the imaging studies that have been
conducted to date because all of these studies used relatively
low 75 or 100 μg doses. In the present study, the 200 μg dose
of LSD produced particularly marked increases in visionary
restructuralization including changed meaning of percepts
which were significantly greater after the 200 compared with
the 100 μg dose. Contrary to expectations, these perceptual
alterations were greater in participants with relatively lower
Cmax levels of LSD within the 200 μg dose group further
supporting the view that higher plasma levels of LSD may
not produce greater subjective alterations above a certain
threshold level and if high doses of LSD are used.
In conclusion, LSD (200 μg) rarely produced full mystical
experiences in the present study and in patients during LSD-
assisted psychotherapy compared with psilocybin in another
set and setting. This raises questions regarding expectancy
effects and placebo responses and the therapeutic role of
mystical experiences. LSD produced significantly greater
bliss, insightfulness, and changes in meaning of percepts at
200 μg compared with 100 μg, in addition to the previously
reported greater empathogenic effects. This could be relevant
for LSD-assisted psychotherapy (200 μg) and the interpreta-
tion of fMRI data (75–100 μg). Generally, no association was
found between plasma LSD levels and its robust effects when
analyzed across different subjects and within a dose group.
This may have implications for studies that interrelate differ-
ent effects of LSD, namely fMRI studies.
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